Please use this identifier to cite or link to this item:
Title: Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition
Author: Schmidt, Julie A.
Fensom, Georgina K.
Rinaldi, Sabina
Scalbert, Augustin
Appleby, Paul N.
Achaintre, David
Gicquiau, Audrey
Gunter, Marc J.
Ferrari, Pietro
Kaaks, Rudolf
Kühn, Tilman
Floegel, Anna
Boeing, Heiner
Trichopoulou, Antonia
Lagiou, Pagona
Anifantis, Eleutherios
Agnoli, Claudia
Palli, Domenico
Trevisan, Morena
Tumino, Rosario
Bueno de Mesquita, H. Bas
Agudo, Antonio
Larrañaga, Nerea
Redondo Sánchez, Daniel
Barricarte, Aurelio
Huerta Castaño, José María
Quirós, J. Ramón
Wareham, Nicholas J.
Khaw, Kay-Tee
Perez Cornago, Aurora
Johansson, Mattias
Cross, Amanda J.
Tsilidis, Konstantinos K.
Riboli, Elio
Key, Timothy J.
Travis, Ruth C.
Keywords: Càncer
Espectrometria de masses
Mass spectrometry
Issue Date: 5-Jul-2017
Publisher: BioMed Central
Abstract: Background: Little is known about how pre-diagnostic metabolites in blood relate to risk of prostate cancer. We aimed to investigate the prospective association between plasma metabolite concentrations and risk of prostate cancer overall, and by time to diagnosis and tumour characteristics, and risk of death from prostate cancer. Methods: In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition, pre-diagnostic plasma concentrations of 122 metabolites (including acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose and sphingolipids) were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit) and compared between 1077 prostate cancer cases and 1077 matched controls. Risk of prostate cancer associated with metabolite concentrations was estimated by multi-variable conditional logistic regression, and multiple testing was accounted for by using a false discovery rate controlling procedure. (Continued on next page) Results: Seven metabolite concentrations, i.e. acylcarnitine C18: 1, amino acids citrulline and trans-4-hydroxyproline, glycerophospholipids PC aa C28: 1, PC ae C30: 0 and PC ae C30: 2, and sphingolipid SM (OH) C14: 1, were associated with prostate cancer (p < 0.05), but none of the associations were statistically significant after controlling for multiple testing. Citrulline was associated with a decreased risk of prostate cancer (odds ratio (OR1SD) = 0.73; 95% confidence interval (CI) 0.62-0.86; ptrend = 0.0002) in the first 5 years of follow-up after taking multiple testing into account, but not after longer follow-up; results for other metabolites did not vary by time to diagnosis. After controlling for multiple testing, 12 glycerophospholipids were inversely associated with advanced stage disease, with risk reduction up to 46% per standard deviation increase in concentration (OR1SD = 0.54; 95% CI 0.40-0.72; ptrend = 0.00004 for PC aa C40: 3). Death from prostate cancer was associated with higher concentrations of acylcarnitine C3, amino acids methionine and trans-4-hydroxyproline, biogenic amine ADMA, hexose and sphingolipid SM (OH) C14: 1 and lower concentration of glycerophospholipid PC aa C42: 4. Conclusions: Several metabolites, i.e. C18:1, citrulline, trans-4-hydroxyproline, three glycerophospholipids and SM (OH) C14:1, might be related to prostate cancer. Analyses by time to diagnosis indicated that citrulline may be a marker of subclinical prostate cancer, while other metabolites might be related to aetiology. Several glycerophospholipids were inversely related to advanced stage disease. More prospective data are needed to confirm these associations.
Note: Reproducció del document publicat a:
It is part of: BMC Medicine, 2017-07-05, Vol. 15
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
SchmidtJA.pdf1.56 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons